Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma

Exclusion Criteria

• •Known history of transformed lymphoma or diffuse large cell lymphoid malignancy
• •Known history of, or clinically apparent, central nervous system (CNS) lymphoma or leptomeningeal lymphoma
• •Evidence of ongoing systemic bacterial, fungal, or viral infection at the time of enrollment
• •Known history of drug-induced liver injury, chronic active hepatitis B (HBV), chronic active hepatitis C (HCV), alcoholic liver disease, non-alcoholic steatohepatitis, cirrhosis of the liver, portal hypertension, primary biliary cirrhosis, or ongoing extrahepatic obstruction caused by cholelithiasis
• •Ongoing inflammatory bowel disease
• •Known human immunodeficiency virus (HIV) infection
• •History of prior allogeneic bone marrow progenitor cell or solid organ transplantation
• •Ongoing immunosuppressive therapy, including systemic corticosteroids (\> 10 mg prednisone or equivalent/day) with the exception of the use of topical, enteric, or inhaled corticosteroids as therapy for comorbid conditions and systemic steroids for autoimmune anemia and/or thrombocytopenia